연구동향 분석
박사

폐 샘암종에서 NKX2-1, FOXA1, TP53과 MDM2의 유전적 변화와 단백질 발현의 의미

김주영 2015년

논문상세정보
인용/피인용
' 폐 샘암종에서 NKX2-1, FOXA1, TP53과 MDM2의 유전적 변화와 단백질 발현의 의미' 의 주제별 논문영향력
논문영향력 선정 방법
논문영향력 요약
주제
  • foxa1
  • lung adenocarcinomas
  • mdm2
  • nkx2-1
  • prognostic factor
  • tp53
동일주제 총논문수 논문피인용 총횟수 주제별 논문영향력의 평균
69 0

0.0%

' 폐 샘암종에서 NKX2-1, FOXA1, TP53과 MDM2의 유전적 변화와 단백질 발현의 의미' 의 참고문헌

  • Zhou L, Lim L, Costa RH, Whitsett JA. Thyroid transcription factor-1, hepatocytenuclear factor-3beta, surfactant protein B, C, and Clara cell secretory protein in developing32mouse lung. The journal of histochemistry and cytochemistry : official journal of theHistochemistry Society. 1996;44(10):1183-93.
  • Zauberman A, Barak Y, Ragimov N, Levy N, Oren M. Sequence-specific DNAbinding by p53: identification of target sites and lack of binding to p53 - MDM2 complexes.The EMBO journal. 1993;12(7):2799-808.30
  • Yemelyanova A, Vang R, Kshirsagar M, Lu D, Marks MA, Shih Ie M, et al.Immunohistochemical staining patterns of p53 can serve as a surrogate marker for TP53mutations in ovarian carcinoma: an immunohistochemical and nucleotide sequencinganalysis. Modern pathology : an official journal of the United States and Canadian Academyof Pathology, Inc. 2011;24(9):1248-53.
  • Xue Q, Sano T, Kashiwabara K, Saito M, Oyama T, Nakajima T. Aberrantexpression of pRb, p16, p14ARF, MDM2, p21 and p53 in stage I adenocarcinomas of thelung. Pathology international. 2002;52(2):103-9.
  • Wolf I, Bose S, Williamson EA, Miller CW, Karlan BY, Koeffler HP. FOXA1:Growth inhibitor and a favorable prognostic factor in human breast cancer. Internationaljournal of cancer Journal international du cancer. 2007;120(5):1013-22.
  • Winslow MM, Dayton TL, Verhaak RG, Kim-Kiselak C, Snyder EL, Feldser DM,et al. Suppression of lung adenocarcinoma progression by Nkx2-1. Nature.2011;473(7345):101-4.
  • Wang YC, Lin RK, Tan YH, Chen JT, Chen CY, Wang YC. Wild-type p53overexpression and its correlation with MDM2 and p14ARF alterations: an alternativepathway to non-small-cell lung cancer. Journal of clinical oncology : official journal of theAmerican Society of Clinical Oncology. 2005;23(1):154-64.
  • Wang H, Meyer CA, Fei T, Wang G, Zhang F, Liu XS. A systematic approachidentifies FOXA1 as a key factor in the loss of epithelial traits during the epithelial-tomesenchymaltransition in lung cancer. BMC genomics. 2013;14:680.
  • Thorat MA, Marchio C, Morimiya A, Savage K, Nakshatri H, Reis-Filho JS, et al.Forkhead box A1 expression in breast cancer is associated with luminal subtype and goodprognosis. Journal of clinical pathology. 2008;61(3):327-32.
  • Tashiro H, Isacson C, Levine R, Kurman RJ, Cho KR, Hedrick L. p53 genemutations are common in uterine serous carcinoma and occur early in their pathogenesis.The American journal of pathology. 1997;150(1):177-85.
  • Tang X, Kadara H, Behrens C, Liu DD, Xiao Y, Rice D, et al. Abnormalities of theTITF-1 lineage-specific oncogene in NSCLC: implications in lung cancer pathogenesis andprognosis. Clinical cancer research : an official journal of the American Association forCancer Research. 2011;17(8):2434-43.
  • Tanaka H, Yanagisawa K, Shinjo K, Taguchi A, Maeno K, Tomida S, et al.Lineage-specific dependency of lung adenocarcinomas on the lung development regulatorTTF-1. Cancer research. 2007;67(13):6007-11.
  • Stenhouse G, Fyfe N, King G, Chapman A, Kerr KM. Thyroid transcription factor 1in pulmonary adenocarcinoma. Journal of clinical pathology. 2004;57(4):383-7.
  • Steels E, Paesmans M, Berghmans T, Branle F, Lemaitre F, Mascaux C, et al. Roleof p53 as a prognostic factor for survival in lung cancer: a systematic review of the literaturewith a meta-analysis. The European respiratory journal. 2001;18(4):705-19.
  • Song Y, Washington MK, Crawford HC. Loss of FOXA1/2 is essential for theepithelial-to-mesenchymal transition in pancreatic cancer. Cancer research. 2010;70(5):2115-25.
  • Saad RS, Liu YL, Han H, Landreneau RJ, Silverman JF. Prognostic significance ofthyroid transcription factor-1 expression in both early-stage conventional adenocarcinomaand bronchioloalveolar carcinoma of the lung. Human pathology. 2004;35(1):3-7.
  • Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al.Erlotinib versus standard chemotherapy as first-line treatment for European patients withadvanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre,open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46.
  • Qiu M, Bao W, Wang J, Yang T, He X, Liao Y, et al. FOXA1 promotes tumor cellproliferation through AR involving the Notch pathway in endometrial cancer. BMC cancer.2014;14:78.
  • Prives C, Hall PA. The p53 pathway. The Journal of pathology. 1999;187(1):112-26.
  • Pelosi G, Fraggetta F, Pasini F, Maisonneuve P, Sonzogni A, Iannucci A, et al.Immunoreactivity for thyroid transcription factor-1 in stage I non-small cell carcinomas ofthe lung. The American journal of surgical pathology. 2001;25(3):363-72.
  • Oxnard GR, Binder A, Janne PA. New targetable oncogenes in non-small-cell lungcancer. Journal of clinical oncology : official journal of the American Society of ClinicalOncology. 2013;31(8):1097-104.
  • Nucera C, Eeckhoute J, Finn S, Carroll JS, Ligon AH, Priolo C, et al. FOXA1 is apotential oncogene in anaplastic thyroid carcinoma. Clinical cancer research : an officialjournal of the American Association for Cancer Research. 2009;15(11):3680-9.33
  • Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib orcarboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57.
  • Mirosevich J, Gao N, Gupta A, Shappell SB, Jove R, Matusik RJ. Expression androle of Foxa proteins in prostate cancer. Prostate. 2006;66(10):1013-28.
  • Minoo P, Hu L, Xing Y, Zhu NL, Chen H, Li M, et al. Physical and functionalinteractions between homeodomain NKX2.1 and winged helix/forkhead FOXA1 in lungepithelial cells. Mol Cell Biol. 2007;27(6):2155-65.
  • Lupien M, Eeckhoute J, Meyer CA, Wang Q, Zhang Y, Li W, et al. FoxA1translates epigenetic signatures into enhancer-driven lineage-specific transcription. Cell.2008;132(6):958-70.
  • Lin L, Miller CT, Contreras JI, Prescott MS, Dagenais SL, Wu R, et al. Thehepatocyte nuclear factor 3 alpha gene, HNF3alpha (FOXA1), on chromosome band 14q13is amplified and overexpressed in esophageal and lung adenocarcinomas. Cancer research.2002;62(18):5273-9.
  • Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick L. The frequency of p53, K-rasmutations, and microsatellite instability differs in uterine endometrioid and serouscarcinoma: evidence of distinct molecular genetic pathways. Cancer. 2000;88(4):814-24.
  • Langendijk JA, Thunnissen FB, Lamers RJ, de Jong JM, ten Velde GP, Wouters EF.The prognostic significance of accumulation of p53 protein in stage III non-small cell lungcancer treated by radiotherapy. Radiotherapy and oncology : journal of the European Societyfor Therapeutic Radiology and Oncology. 1995;36(3):218-24.
  • Kwak EL, Bang YJ, Camidge DR, Shaw AT, Solomon B, Maki RG, et al.31Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med.2010;363(18):1693-703.
  • Koga T, Hashimoto S, Sugio K, Yoshino I, Nakagawa K, Yonemitsu Y, et al.Heterogeneous distribution of P53 immunoreactivity in human lung adenocarcinomacorrelates with MDM2 protein expression, rather than with P53 gene mutation. Internationaljournal of cancer Journal international du cancer. 2001;95(4):232-9.
  • Ko JL, Cheng YW, Chang SL, Su JM, Chen CY, Lee H. MDM2 mRNA expressionis a favorable prognostic factor in non-small-cell lung cancer. International journal of cancerJournal international du cancer. 2000;89(3):265-70.
  • Khor LY, Bae K, Paulus R, Al-Saleem T, Hammond ME, Grignon DJ, et al. MDM2and Ki-67 predict for distant metastasis and mortality in men treated with radiotherapy andandrogen deprivation for prostate cancer: RTOG 92-02. Journal of clinical oncology : officialjournal of the American Society of Clinical Oncology. 2009;27(19):3177-84.
  • Kawase M, Toyama T, Takahashi S, Sato S, Yoshimoto N, Endo Y, et al. FOXA1expression after neoadjuvant chemotherapy is a prognostic marker in estrogen receptorpositivebreast cancer. Breast Cancer. 2013.
  • Katoh M, Igarashi M, Fukuda H, Nakagama H, Katoh M. Cancer genetics andgenomics of human FOX family genes. Cancer Lett. 2013;328(2):198-206.
  • Kaserer K, Schmaus J, Bethge U, Migschitz B, Fasching S, Walch A, et al. Stainingpatterns of p53 immunohistochemistry and their biological significance in colorectal cancer.34The Journal of pathology. 2000;190(4):450-6.
  • Kanters SD, Lammers JW, Voest EE. Molecular and biological factors in theprognosis of non-small cell lung cancer. The European respiratory journal. 1995;8(8):1389-97.
  • Jain RK, Mehta RJ, Nakshatri H, Idrees MT, Badve SS. High-level expression offorkhead-box protein A1 in metastatic prostate cancer. Histopathology. 2011;58(5):766-72.
  • Higashiyama M, Doi O, Kodama K, Yokouchi H, Kasugai T, Ishiguro S, et al.MDM2 gene amplification and expression in non-small-cell lung cancer:immunohistochemical expression of its protein is a favourable prognostic marker in patientswithout p53 protein accumulation. British journal of cancer. 1997;75(9):1302-8.
  • Gorgoulis VG, Zacharatos PV, Manolis E, Ikonomopoulos JA, Damalas A,Lamprinopoulos C, et al. Effects of p53 mutants derived from lung carcinomas on the p53-responsive element (p53RE) of the MDM2 gene. British journal of cancer. 1998;77(3):374-84.
  • Friedman JR, Kaestner KH. The Foxa family of transcription factors indevelopment and metabolism. Cell Mol Life Sci. 2006;63(19-20):2317-28.
  • Eymin B, Gazzeri S, Brambilla C, Brambilla E. Mdm2 overexpression andp14(ARF) inactivation are two mutually exclusive events in primary human lung tumors.Oncogene. 2002;21(17):2750-61.
  • Deutsch L, Wrage M, Koops S, Glatzel M, Uzunoglu FG, Kutup A, et al. Oppositeroles of FOXA1 and NKX2-1 in lung cancer progression. Genes, chromosomes & cancer.2012;51(6):618-29.
  • D'Amico TA, Massey M, Herndon JE, 2nd, Moore MB, Harpole DH, Jr. A biologicrisk model for stage I lung cancer: immunohistochemical analysis of 408 patients with theuse of ten molecular markers. The Journal of thoracic and cardiovascular surgery.1999;117(4):736-43.
  • Chen X, Qiu J, Yang D, Lu J, Yan C, Zha X, et al. MDM2 promotes invasion andmetastasis in invasive ductal breast carcinoma by inducing matrix metalloproteinase-9. PloSone. 2013;8(11):e78794.
  • Besnard V, Wert SE, Hull WM, Whitsett JA. Immunohistochemical localization ofFoxa1 and Foxa2 in mouse embryos and adult tissues. Gene expression patterns : GEP.2004;5(2):193-208.
  • Berghmans T, Paesmans M, Mascaux C, Martin B, Meert AP, Haller A, et al.Thyroid transcription factor 1--a new prognostic factor in lung cancer: a meta-analysis.Annals of oncology : official journal of the European Society for Medical Oncology / ESMO.2006;17(11):1673-6.
  • Berghmans T, Mascaux C, Haller A, Meert AP, Van Houtte P, Sculier JP. EGFR,TTF-1 and Mdm2 expression in stage III non-small cell lung cancer: a positive association.Lung cancer. 2008;62(1):35-44.
  • Berghmans T, Lafitte JJ, Thiriaux J, VanHoutte P, Lecomte J, Efremidis A, et al.Survival is better predicted with a new classification of stage III unresectable non-small celllung carcinoma treated by chemotherapy and radiotherapy. Lung cancer. 2004;45(3):339-48.
  • Barlesi F, Pinot D, Legoffic A, Doddoli C, Chetaille B, Torre JP, et al. Positivethyroid transcription factor 1 staining strongly correlates with survival of patients withadenocarcinoma of the lung. British journal of cancer. 2005;93(4):450-2.
  • Barak Y, Juven T, Haffner R, Oren M. mdm2 expression is induced by wild typep53 activity. The EMBO journal. 1993;12(2):461-8.
  • Badve S, Turbin D, Thorat MA, Morimiya A, Nielsen TO, Perou CM, et al.FOXA1 expression in breast cancer--correlation with luminal subtype A and survival.Clinical cancer research : an official journal of the American Association for CancerResearch. 2007;13(15 Pt 1):4415-21.
  • Au NH, Cheang M, Huntsman DG, Yorida E, Coldman A, Elliott WM, et al.Evaluation of immunohistochemical markers in non-small cell lung cancer by unsupervisedhierarchical clustering analysis: a tissue microarray study of 284 cases and 18 markers. TheJournal of pathology. 2004;204(1):101-9.
  • Andre F, Grunenwald D, Pignon JP, Dujon A, Pujol JL, Brichon PY, et al. Survivalof patients with resected N2 non-small-cell lung cancer: evidence for a subclassification andimplications. Journal of clinical oncology : official journal of the American Society ofClinical Oncology. 2000;18(16):2981-9.
  • Anagnostou VK, Syrigos KN, Bepler G, Homer RJ, Rimm DL. Thyroidtranscription factor 1 is an independent prognostic factor for patients with stage I lungadenocarcinoma. Journal of clinical oncology : official journal of the American Society ofClinical Oncology. 2009;27(2):271-8.
  • ?1. Berghmans T, Mascaux C, Martin B, Ninane V, Sculier JP. Prognostic role of p53in stage III non-small cell lung cancer. Anticancer research. 2005;25(3c):2385-9.